Founded in 2003, Asymmetric Therapeutics, LLC is dedicated to pioneering advances
in organ protection during systemic anti-cancer therapy.
Systemic administration of antineoplastic chemical agents (chemotherapy) has been a mainstay of cancer treatment for the past 50 years. Despite success against an ever greater number of cancers, systemic administration of these toxic agents is often attended by painful,deleterious side-effects that limit their clinical usefulness.
Chemotherapeutic drugs attack not only the fast growing cells of a cancerous tumor, but may also damage normal tissues of the body. Healthy tissues most often affected include the lining of the mouth, the lining of the intestine,
the hair and the palmar and plantar surfaces.
Asymmetric Therapeutic's innovations include patented methods, compositions and kits for the treatment of common side-effects of chemotherapy such as nausea, diarrhea, and Hand-Foot Syndrome.
The work of Asymmetric Therapeutics in the medical field has launched two spin-off companies, aimed at tackling different challenges we have encountered in healthcare:
Triaged Data Display (TDD) is a successfully tested technology that presents information in a single screen for efficient report visualization and triaging. The single-display format used in TDD has been shown in a peer-reviewed publication to be superior to leading reporting platforms.
Brain Fit Imaging is the creator of MIND.MEG, a clinical assessment
based on features derived from magnetoencephalography. It provides
a real time assessment of cognitive function, and allows for the evaluation of cognitive effects of therapeutic interventions of all types.
